anti cdk4 (Cell Signaling Technology Inc)
Structured Review
Anti Cdk4, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 968 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cdk4/CDK4+Rabbit+mAb/pm41874002-195-26-27
Average 96 stars, based on 968 article reviews
Images
Related Articles
other:Article Title: Histone acetyltransferase 1 promotes ovarian cancer progression by regulating cell proliferation and the cell cycle Article Snippet: The following primary antibodies were used in the present study: Anti-HAT1 (1:1,000; cat no. 11432-1-AP; Proteintech Group, Inc.), anti-CDK2 (1:1,000; cat no. 10122-1-AP; Proteintech Group, Inc.), anti-FOXA1 (1:1,000; cat no. 20411-1-AP; Proteintech Group, Inc.), Article Title: Repurposing T-type calcium channel blocker Lomerizine as a therapeutic strategy for glioblastoma. Article Snippet: The following primary antibodies were 464 used in this study: Article Title: Integrative Mechanistic Investigation of the Anticancer Effects of Panax notoginseng in Colorectal Cancer. Article Snippet: Article Title: Integrative Mechanistic Investigation of the Anticancer Effects of Panax notoginseng in Colorectal Cancer Article Snippet: Article Title: Ring Finger Protein 1, a Novel Ubiquitin E3 Ligase Targeting Cancerous Inhibitor of Protein Phosphatase 2A to Suppress Smoking‐Induced Lung Tumorigenesis Article Snippet: The primary antibodies were purchased as follows: anti‐CIP2A (#SC‐80659, Santa Cruz Biotechnology), Article Title: VPS35 Deficiency Markedly Reduces the Proliferation of HEK293 Cells Article Snippet: The following primary antibodies were used: anticaspase-3 (9662S; 1:3000), anti-poly(ADP-ribose) polymerase (PARP; 9542S; 1:3000), anticytochrome C (11940S; 1:1000), anti-CDK4 (12790S; 1:2000), anti-cyclinD1 (2978S; 1:3000), anti-Drp1 (8570S; 1:3000), and Article Title: VPS35 Deficiency Markedly Reduces the Proliferation of HEK293 Cells Article Snippet: The following primary antibodies were used: anti-caspase-3 (9662S; 1:3000), anti-poly(ADP-ribose) polymerase (PARP; 9542S; 1:3000), anticytochrome C (11940S; 1:1000), anti-CDK4 (12790S; 1:2000), anti-cyclinD1 (2978S; 1:3000), anti-Drp1 (8570S; 1:3000), and Control:Article Title: Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy. Article Snippet: Phosphoenolpyruvate carboxykinase 1 (PCK1) is known for its role in gluconeogenesis and the regulation of PCK1 expression was shown to associate with oncogenic activity in pancreatic and colorectal cancers.. However, in different cancer types such as liver cancer, PCK1 could function as a tumor suppressor, rendering complication for targeted therapy.. In this study, we used breast cancer model to delineate its involvement in malignancy, we found PCK1 associated with oncogenic function to promotes cell proliferation, enhances colony formation, and stimulates DNA synthesis in breast cancer. |

